BACKGROUND: We assessed whether adding the biomarkers Pregnancy Associated Plasma Protein-A (PAPP-A) and Placental Growth Factor (PlGF) to maternal clinical characteristics improved the prediction of a previously developed model for gestational hypertension in a cohort of Ghanaian pregnant women. METHODS: This study was nested in a prospective cohort of 1010 pregnant women attending antenatal clinics in two public hospitals in Accra, Ghana. Pregnant women who were normotensive, at a gestational age at recruitment of between 8 and 13 weeks and provided a blood sample for biomarker analysis were eligible for inclusion. From serum, biomarkers PAPP-A and PlGF concentrations were measured by the AutoDELFIA immunoassay method and multiple of the ...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
INTRODUCTION: Prediction models for gestational hypertension and preeclampsia have been developed wi...
Objective: To assess first trimester placental growth factor (PlGF) and pregnancy-associated plasma ...
BACKGROUND: We assessed whether adding the biomarkers Pregnancy Associated Plasma Protein-A (PAPP-A)...
We assessed whether adding the biomarkers Pregnancy Associated Plasma Protein-A (PAPP-A) and Placent...
Background: Baseline distributions of pregnancy disorders' biomarkers PlGF and PAPP-A levels are pri...
Hypertensive disorders of pregnancy are important causes of maternal morbidity and mortality. This t...
Baseline distributions of pregnancy disorders' biomarkers PlGF and PAPP-A levels are primarily based...
Objective To develop and validate a prediction model for identifying women at increased risk of deve...
In a previous study, we have described the predictive value of first-trimester Pregnancy-Associated ...
ObjectiveTo investigate the prediction of preeclampsia and gestational hypertension using maternal c...
In a previous study, we have described the predictive value of first-trimester Pregnancy-Associated ...
Background: The prediction of hypertension in first trimester is fairly a new concept in recent year...
Preeclampsia (PE) is the leading cause of poor maternal and perinatal outcomes in both developed and...
Background: Pre eclampsia complicates around 5-10% of pregnancies worldwide. Many countries in the w...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
INTRODUCTION: Prediction models for gestational hypertension and preeclampsia have been developed wi...
Objective: To assess first trimester placental growth factor (PlGF) and pregnancy-associated plasma ...
BACKGROUND: We assessed whether adding the biomarkers Pregnancy Associated Plasma Protein-A (PAPP-A)...
We assessed whether adding the biomarkers Pregnancy Associated Plasma Protein-A (PAPP-A) and Placent...
Background: Baseline distributions of pregnancy disorders' biomarkers PlGF and PAPP-A levels are pri...
Hypertensive disorders of pregnancy are important causes of maternal morbidity and mortality. This t...
Baseline distributions of pregnancy disorders' biomarkers PlGF and PAPP-A levels are primarily based...
Objective To develop and validate a prediction model for identifying women at increased risk of deve...
In a previous study, we have described the predictive value of first-trimester Pregnancy-Associated ...
ObjectiveTo investigate the prediction of preeclampsia and gestational hypertension using maternal c...
In a previous study, we have described the predictive value of first-trimester Pregnancy-Associated ...
Background: The prediction of hypertension in first trimester is fairly a new concept in recent year...
Preeclampsia (PE) is the leading cause of poor maternal and perinatal outcomes in both developed and...
Background: Pre eclampsia complicates around 5-10% of pregnancies worldwide. Many countries in the w...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
INTRODUCTION: Prediction models for gestational hypertension and preeclampsia have been developed wi...
Objective: To assess first trimester placental growth factor (PlGF) and pregnancy-associated plasma ...